BIAF

NASDAQ Healthcare

bioAffinity Technologies, Inc. - Common Stock

Diagnostics & Research

bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person's sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. The company has a collaboration with Brooke Army Medical Center to evaluate its proprietary tests under development to identify inflammatory biomarkers for asthma and chronic obstructive pulmonary disease. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.

๐Ÿ“Š Market Data
Price$9.43
Volume10,341,835
Market Cap5.66M
Beta-1.110
RSI (14-Day)57.1
200-Day MA$21.63
50-Day MA$8.35
52-Week High$109.35
52-Week Low$4.56
Forward P/E-15.72
Price / Book1.13
๐ŸŽฏ Investment Strategy Scores

BIAF scores across each investment strategy. Higher is better for that strategy's goals.

High dividend yield + low volatility
Contrarian plays (oversold + below moving average)
Overbought stocks (potential short candidates)
๐Ÿ” Strategy Interpretation

Best fit: ๐Ÿ”ช Falling Knife (98/100) โ€” this strategy Contrarian plays (oversold + below moving average).

Lowest fit among scored strategies: ๐Ÿ’ฐ Dividend Daddy (23/100). No single score is a buy or sell signal โ€” use multiple lenses together. Learn how to read these scores โ†’

Find BIAF in your text

Paste any article, transcript, or post โ€” the tool will extract BIAF and every other hidden ticker.

Try the Ticker Extractor โ†’

Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-09-18.